Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Human Albumin Industry Report 2014" report ... Albumin Industry Report 2014 is a professional and in-depth ... albumin industry. The report provides a basic ... industry chain structure. The human albumin market analysis is ...
    (Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
    (Date:9/18/2014)... Woburn, MA (PRWEB) September 18, 2014 ... Single Molecule Sequencing (tSMS™) technology, announced today the ... round of investment, led by Genomic Diagnostic Technologies, ... scientific and diagnostic applications. , Founded in March ... Scientist and Bioinformatics Analyst at Helicos BioSciences, SeqLL ...
    (Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
    Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Using solar energy to turn raw materials into ingredients for every day life 2
    ... University of Wisconsin Medical Foundation is initiating ... Foundation's clinical data and to improve the reliability of ... QDX Platform V Integration Services from Quovadx, ... in Englewood, Colorado. , ,The Medical Foundations growth ...
    ... of single-molecule DNA analysis technology, announced Thursday it has commenced ... tumor, known as oligodendroglioma. OpGen, based in Madison, is working ... of genetics and chemistry at the University of Wisconsin-Madison and ... mapping, invented by Schwartz, will enable researchers to determine how ...
    ... weeks ago, I referred to offshore outsourcing as an ... an issue de lannee (an election year at that ... questions about the economic future of the U.S. Prominent ... the contenders for the Democratic presidential nomination to the ...
    Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2The Great Offshore Outsourcing Debate 2
    (Date:9/18/2014)... are the ideal animal in which to study the ... ocean into tens of thousands of freshwater streams and ... to adapt to the new environment. , Breeding studies ... turned up one of the genes that controls tooth ... gene,s regulation in a freshwater population is associated with ...
    (Date:9/17/2014)... creation of the Santa Ana Wildfire Threat Index ... of the powerful, hot, dry Santa Ana wind, which ... was introduced Sept. 17 by the U.S. Forest Service, ... Electric. , The index includes four classification levels ranging ... help fire agencies and other emergency responders, the media ...
    (Date:9/17/2014)... USA -- "Nature has developed, very cleverly, some lessons ... in optical design," said Joseph Shaw, director of the ... explore surfaces and structures at the nanoscale, we,ll discover ... San Diego in August during a conference called "The ... and Rongguang Liang of the University of Arizona College ...
    Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
    ... LA Research led by Lauren Cole, a public ... of Public Health and Director of the Epidemiology Program ... the incidence of head and neck cancer has risen ... with the greatest increase among middle-aged white men. At ...
    ... gene called XRCC2 cause increased breast cancer risk, according to ... Human Genetics . The study looked at families that have ... in the currently known breast cancer susceptibility genes. Sean ... professor in the Department of Oncological Sciences at the University ...
    ... such as the Iberian lynx, are under an increasingly serious ... that can even survive in extremely arid environments. A study ... to adapt according to climate. The life cycle of ... patterns of people and goods. These parasites and the pathogens ...
    Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2A new breast cancer susceptibility gene 2Ticks can adapt to the Spain's climatic diversity 2
    Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
    ... The involvement of integrins in vascular proliferation, ... The integrin family of cell adhesion receptors ... composed of an a and b subunit ... structure and functional diversity of the integrin ...
    ... exchange media are rigid macroporous hydrophilic media. ... rates at moderate pressures, while the macroporous ... the hydrophilic matrix reduces nonspecific binding. Macro-Prep ... anion exchanger with very high flow rates ...
    ... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
    Biology Products: